Pro variant of TP53 Arg72Pro contributes to esophageal squamous cell carcinoma risk: Evidence from a meta-analysis

European Journal of Cancer Prevention

Volumn 19, Issue 4, 2010, Pages 299-307

  Wang, Bin ^a   Wang, Dan ^d   Zhang, Deqiang ^c   Li, Aijun ^b   Liu, Dawei ^b   Liu, Hu ^b   Jin, Hai ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal cancer; Esophageal squamous cell carcinoma; Gene polymorphism; Meta analysis; TP53 Arg72Pro

Indexed keywords

ARGININE; PROLINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIMER INTRODUCED RESTRICTION ANALYSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ARGININE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROLINE; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77953535612     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32833964bc     Document Type: Article

References (56)

1. Bojesen SE, Nordestgaard BG (2008). The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 7:158-163.
2. Brown LM, Hoover R, Silverman D, Baris D, Hayes R, Swanson GM, et al. (2001). Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 153:114-122.
3. Cai L, Mu LN, Lu H, Lu QY, You NC, Yu SZ, et al. (2006). Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 15:294-300.
4. Cao YY, Ge H, Chen LQ, Chen ZF, Wen DG, Li Y, et al. (2007). Correlation of 53BP1 and p53 polymorphisms with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng 26:1052-1057. [Article in Chinese]
5. Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, et al. (2003). Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125:1121-1131.
6. Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, et al. (2009). p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res 15:3103-3109.
7. Chen WQ (2009). Estimation of cancer incidence and mortality in China in 2004-2005. Zhong Hua Zhong Liu Za Zhi 31:664-668. [Article in Chinese]
8. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR (2005). PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309:1732-1735.
9. Cochran WG (1954). The combination of estimates from different experiments. Biometrics 10:101-129.
10. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
11. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365.
12. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
13. Enzinger PC, Mayer RJ (2003). Esophageal cancer. N Engl J Med 349: 2241-2252.
14. Galic V,Willner J,Wollan M, Garg R, Garcia R, Goff BA, et al. (2007). Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46:239-247.
15. Goan YG, Chang HC, Hsu HK, Chou YP, Cheng JT (2005). Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese. Cancer Sci 96:758-765.
16. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, et al. (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 181:81-85.
17. Han JY, Lee GK, Jang DH, Lee SY, Lee JS (2008). Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113:799-807.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ 327:557-560.
19. Hiyama T, Yoshihara M, Tanaka S, Chayama K (2007). Genetic polymorphisms and esophageal cancer risk. Int J Cancer 121:1643-1658.
20. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. (2005). The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582-9587.
21. Hu N, Li WJ, Su H, Wang C, Goldstein AM, Albert PS, et al. (2003). Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China. Cancer Detect Prev 27:132-138.
22. Hu Z, Li X, Yuan R, Ring BZ, Su L (2010). Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120:705-714.
23. Huang ZH, Hua D, Du X (2009). Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64:1001-1007.
24. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. (2007). Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 37:120-132.
25. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
26. Kashima T, Makino K, Soemantri A, Ishida T (2007). TP53 codon 72 polymorphism in 12 populations of insular southeast Asia and Oceania.J HumGenet 52:694-697.
27. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, et al. (2009). TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64:355-360.
28. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 10:772-784.
29. Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, et al. (2000). Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 89:458-464.
30. Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, et al. (2010). p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus 23:36-39.
31. Luu TD, Gaur P, Force SD, Staley CA, Mansour KA, Miller JI Jr, et al. (2008). Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann Thorac Surg 85:1217-1223.
32. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
33. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. (2007). Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: fiveyear survival of a randomized clinical trial. Ann Surg 246:992-1000.
34. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55:74-108.
35. Peixoto GD, Hsin Lu S, Snijders P,Wilmotte R, Herrero R, Lenoir G, et al. (2001). Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett 162:231-235.
36. Pohl H, Welch HG (2005). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142-146. (Pubitemid 40277094)
37. Riley T, Sontag E, Chen P, Levine A (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
38. Ruol A, Castoro C, Portale G, Cavallin F, Sileni VC, Cagol M, et al. (2009). Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg 144:247-254.
39. Shao Y, Tan W, Zhang S (2008). P53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population. Dis Esophagus 21:139-143.
40. Shimada H, Shiratori T, Okazumi S, Matsubara H, Nabeya Y, Shuto K, et al. (2008). Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg 206:48-56.
41. Själander A, Birgander R, KiveläA, Beckman G (1995). p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45:144-149.
42. Soussi T (2007). p53 alterations in human cancer: more questions than answers. Oncogene 26:2145-2156.
43. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100.
44. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, et al. (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34.
45. Vogelstein B, Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10:789-799.
46. Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature 408:307-310.
47. Vos M, Adams CH, Victor TC, van Helden PD (2003). Polymorphisms and mutations found in the regions flanking exons 5-8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet 140:23-30.
48. Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283.
49. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95-107.
50. Woolf B (1955). On estimating the relation between blood group and disease. Ann Hum Genet 19:251-253.
51. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, et al. (2009). TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 125:2903-2911.
52. Yang W, Zhang Y, Tian X, Ning T, Ke Y (2008). p53 Codon 72 polymorphism and the risk of esophageal squamous cell carcinoma. Mol Carcinog 47:100-104.
53. Zhang L, Xing D, He Z, Lin D (2002). p53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19:10-13. [Article in Chinese] (Pubitemid 34151597)
54. Zhang JH, Li Y,Wang R,Wen DG,Wu ML, He M (2003). p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population. Zhong Hua Zhong Liu Za Zhi 25:365-367. [Article in Chinese]
55. Zhang Z,Wang M,Wu D,Wang M, Tong N, Tian Y, et al. (2010). P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 120:509-517.
56. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121:1481-1486.